FIGURE 1.

Dasatinib, but not imatinib or nilotinib, alters barrier properties of HMVEC-L and HPAEC cells. HMVEC-L or HPAEC cells were treated with clinically relevant concentrations of dasatinib (100 nM), imatinib (5 μM), nilotinib (100 nM) or vehicle (ctrl: 0.1% DMSO). Cell impedance (transendothelial electrical resistance/TEER or cell index/CI) was followed for 24 h. TEER of HMVEC-L cells was normalized to values before treatments (TEER₀) (A). CI of HMVEC-L and HPAEC cells were normalized to values before treatments (CI₀) (B,C). Permeability of HMVEC-L and HPAEC cells to 4 kDa FITC-dextran was measured after 24 h exposure to TKIs (D,E). Data analysis was done by two-way (A–C) or one-way (D,E) ANOVA with Tukey post hoc test. Values are presented as mean ± SD; ^∗p < 0.05, ^‡p < 0.01, ⁺p < 0.001, ^∙p < 0.0001 compared to ctrl. Representative results of three (N = 3, A,D), five (N = 5, B), four (N = 4, C) or two (N = 2, E) independent experiments are shown.